Monoclonal antibody-drug conjugateFDA-approvedSecond-line

Ado-trastuzumab emtansine

How it works

Delivers a toxic payload to HER2-positive cancer cells, killing them.

Cancer types

Breast CancerHER2-positive

Efficacy

In clinical trials, ado-trastuzumab emtansine improved progression-free survival and response rates in HER2-positive patients with advanced breast cancer.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.